SVRA Savara Inc

Price (delayed)

$5.31

Market cap

$1.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.56

Enterprise value

$1.08B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management ...

Highlights
Savara's equity has increased by 19% YoY but it has decreased by 13% from the previous quarter
SVRA's quick ratio is up by 13% from the previous quarter but it is down by 10% YoY
SVRA's net income is down by 27% YoY and by 9% from the previous quarter
The company's EPS fell by 17% YoY and by 6% QoQ

Key stats

What are the main financial stats of SVRA

SVRA stock price

How has the Savara stock price performed over time
Intraday
1.14%
1 week
4.32%
1 month
0.19%
1 year
113.25%
YTD
-11.94%
QTD
-2.75%

Financial performance

How have Savara's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$134.1M
Net income
-$129.48M
Gross margin
N/A
Net margin
N/A
SVRA's net income is down by 27% YoY and by 9% from the previous quarter
Savara's operating income has decreased by 23% YoY and by 9% from the previous quarter

Price vs fundamentals

How does SVRA's price correlate with its fundamentals

Growth

What is Savara's growth rate over time

Valuation

What is Savara stock price valuation
P/E
N/A
P/B
6.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 17% YoY and by 6% QoQ
The stock's price to book (P/B) is 85% more than its 5-year quarterly average of 3.3 and 9% more than its last 4 quarters average of 5.6
Savara's equity has increased by 19% YoY but it has decreased by 13% from the previous quarter

Efficiency

How efficient is Savara business performance
SVRA's ROE is down by 32% YoY and by 3.8% from the previous quarter
Savara's ROIC has decreased by 32% YoY and by 7% from the previous quarter
SVRA's return on assets is down by 27% year-on-year and by 4.4% since the previous quarter

Dividends

What is SVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SVRA.

Financial health

How did Savara financials performed over time
The total assets has grown by 17% YoY but it has contracted by 13% from the previous quarter
SVRA's current ratio is up by 14% since the previous quarter but it is down by 10% year-on-year
The debt is 83% smaller than the equity
Savara's equity has increased by 19% YoY but it has decreased by 13% from the previous quarter
The debt to equity has contracted by 15% YoY but it has grown by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.